Skip to main content
EDIT
NASDAQ Life Sciences

Editas 10-Q: $190.2M Cash, Runway Into 2H 2028, Q3 Loss Narrows to $23.4M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$2.75
Mkt Cap
$422.345M
52W Low
$1.66
52W High
$3.94
52W Position info
66% above low
Off High info
30% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

EDIT sits 66% above its 52-week low of $1.66.

Summary

Editas closed Q3 with $190.2 million in cash and securities and says that funds operations into the second half of 2028, against a narrowed $23.4 million quarterly loss. The 10-Q also details post-quarter ATM sales of 677,178 shares for $1.9 million and a new CMO's compensation package.


Key Events · Earnings and Guidance · EDIT

  • Q3 Loss Narrows to $23.4M

    Net loss of $23.4 million ($0.15 per share) versus $25.1 million a year ago, on collaboration and other R&D revenue of $10.4 million, up from $7.5 million.

  • Cash of $190.2M, Runway to 2H 2028

    Cash, cash equivalents and marketable securities totaled $190.2 million at September 30, 2026; management expects this to fund operations into the second half of 2028.

  • Burn Rate Roughly $74M Year-to-Date

    Net cash used in operating activities was $73.8 million for the nine months ended September 30, 2026, versus $128.9 million a year earlier after the reni-cel wind-down.

  • ATM Drip: 677,178 Shares for $1.9M

    After quarter-end through November 6, 2026, Editas sold 677,178 shares under the $150 million Leerink ATM at a $2.87 weighted average for $1.9 million gross; no shares had been sold as of September 30.


Analysis · EDIT · Life Sciences

The headline numbers were already out this morning via 8-K, but the full 10-Q is where the balance sheet and runway live: $190.2 million of cash and securities at September 30 funds operations into the second half of 2028, which is what actually matters for a pre-revenue gene editing company burning roughly $74 million of operating cash in nine months. The quarter itself was clean — revenue rose to $10.4 million on partner milestones and the net loss narrowed to $23.4 million ($0.15 per share) from $25.1 million a year ago. The dilution story is already in the share count: 153.7 million shares outstanding versus 97.9 million at year-end after the May offering of 55.6 million shares plus 55.6 million warrants struck at $3.50, none exercised. The company also disclosed it sold 677,178 shares under the new Leerink ATM at a $2.87 weighted average for $1.9 million after quarter-end, a slow drip rather than a flood. Next hard data point is initial EDIT-401 safety and tolerability data from the Strive trial, guided to the first quarter of 2027.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EDIT was trading at $2.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $422.3M. The 52-week trading range was $1.66 to $3.94. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EDIT - Latest Insights

EDIT
Nov 09, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.61
Real-time Price: $2.80 info
Change: +$0.190 (+7%) info
Market Cap: $422.345M info
EDIT
Nov 09, 2026, 7:01 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $2.61
Real-time Price: $2.80 info
Change: +$0.190 (+7%) info
Market Cap: $422.345M info
EDIT
Oct 08, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.80
Real-time Price: $2.80 info
Change: $0 (0%) info
Market Cap: $422.345M info
EDIT
Oct 08, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.73
Real-time Price: $2.80 info
Change: +$0.070 (+3%) info
Market Cap: $422.345M info
EDIT
May 26, 2026, 5:30 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $2.98
Real-time Price: $2.80 info
Change: -$0.180 (-6%) info
Market Cap: $422.345M info